In our study, the median OS for monotherapy-treated PS0-1 patients was 23.8 months for NSQ and 13.3 months for SQ NSCLC with tumor cell PD-L1 expression ≥50% (Table 3), which is generally in line with pivotal PD-(L)1 inhibitor clinical trials. The gene discussed is CD274; the disease is neoplasm.